WuXi XDC Cayman Inc

Chart & Performance

D1W1MN

P/E

68.96

P/S

18.20

EPS

0.89

Div Yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

4.05b

+90.80%

Net income

1.07b

+277.24%

CFO

717m

+115.48%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

URL

https://wuxixdc.com/

IPO date

Nov 17, 2023

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT